[go: up one dir, main page]

WO2009070012A1 - Capsules de probiotiques à base de protéines - Google Patents

Capsules de probiotiques à base de protéines Download PDF

Info

Publication number
WO2009070012A1
WO2009070012A1 PCT/NL2008/000266 NL2008000266W WO2009070012A1 WO 2009070012 A1 WO2009070012 A1 WO 2009070012A1 NL 2008000266 W NL2008000266 W NL 2008000266W WO 2009070012 A1 WO2009070012 A1 WO 2009070012A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
encapsulate
cross
links
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2008/000266
Other languages
English (en)
Inventor
Aart Cornelis Alting
Theodorus Arnoldus Gerardus Floris
Fanny Chantal Jacqueline Weinbreck
Jeroen Grandia
Freddie Van De Velde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NIZO FOOD RESEARCH BV
Nizo Food Res BV
Original Assignee
NIZO FOOD RESEARCH BV
Nizo Food Res BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NIZO FOOD RESEARCH BV, Nizo Food Res BV filed Critical NIZO FOOD RESEARCH BV
Publication of WO2009070012A1 publication Critical patent/WO2009070012A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/14—Polymerisation; cross-linking
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to protein-based probiotic encapsulates, more particularly to encapsulates that comprise a protein-based encapsulation matrix holding one or more probiotics.
  • the probiotics contained in the encapsulates of the present invention are protected very effectively against gastric conditions.
  • Probiotic bacterial cultures are intended to assist the body's naturally occurring gut flora to reestablish themselves. They are sometimes recommended by doctors, and, more frequently, by nutritionists, after a course of antibiotics, or as part of the treatment for gut-related candidiasis. However, when probiotics are ingested (e.g. enteraly or by inhalation), these first have to pass and survive the extreme conditions existing in the stomach, before they reach the intestines.
  • Encapsulation techniques have been developed to protect components against the detrimental effects of e.g. oxygen, moisture, heat, light or chemical reactions and further to control the release of encapsulated components under conditions of use.
  • Acceptable encapsulating agents must be safe, food-grade and non-hazardous to the consumer's health. For food products it should have a bland or no flavor.
  • Suitable encapsulation agents for food applications include natural gums, carbohydrates, fats and waxes and some proteins. Whereas gum Arabic is one of the most widely used encapsulation agent in food applications the use of proteins is limited.
  • the main protein that has been evaluated for encapsulation is gelatin. Gelatin has been successfully applied as encapsulation agent in the pharmaceutical industry.. However, due to the high viscosity of aqueous gelatin solutions, gelatin has limited use in spray-drying processes.
  • US 5,601,760 describes a method for microencapsulation of a volatile or a non- volatile core material in an encapsulation agent consisting essentially of a whey protein. It is described that whey protein isolate and whey protein concentrate, optionally in combination with milk-derived or non-milk derived carbohydrates, and also ⁇ -lactoglobulin and mixtures of ⁇ -lactoglobulin and ⁇ -lactalbumin were used in a spray-drying encapsulation process. The resulting encapsulates were said to protect the core against deterioration by oxygen or from detrimental of other compounds or materials, to limit the evaporation or losses of volatile core materials and to release the core upon full hydration reconstitution.
  • One example describes encapsulation of anhydrous milk fat in whey protein isolate that has been heated at 80 0 C for 30 minutes. This treatment results in denaturation of whey proteins. The publication is silent on probiotics.
  • the inventors have discovered that the aforementioned objective can be realized by encapsulating a Gram-positive probiotic bacterial strain, in a matrix of protein that has been cross-linked by means of disulfide cross-links. It was found that these disulfide cross-linkages make the encapsulates acid resistant, i.e. the particles remain intact in the stomach and the sensitive probiotic core components, only to be released when contacted with enzymes secreted into the lower intestinal tract, such as pancreatic enzymes. In particular if a protein is utilized that is capable of forming a plurality of disulfide cross-links per molecule, it is possible to produce a cross-linked protein-based matrix that is virtually insoluble.
  • Protein matrices that exhibit a high degree of disulfide cross-linking are further characterized by a very poor water solubility.
  • encapsulates containing a disulfide cross-linked protein- based matrix in accordance with the present invention continue to effectively protect the probiotic component if exposed to moisture, in particular acid.
  • Proteins that can suitably be cross-linked by disulfide links include proteins that contain amino acid residues with a thiol-group, notably cystein. Provided these cystein groups have been 'activated' in a suitable manner, cystein groups in different protein molecules can react with each other, thereby linking these protein molecules by a disulfide cross-link. Not only cystein residues that have free thiol groups can participate in these cross- linking reactions, but also cystein residues that together form a disulfide bridge can react with a thiol group under the formation of a new disulfide bridge and the release of another free thiol group.
  • ⁇ -lactoglobulin can suitably be used as a cross-linkable protein even though this protein normally contains two pairs of cystein residues that form disulfide bridges and only one cystein residue that contains a free thiol group.
  • proteins that are capable of forming disulfide cross-links include whey proteins, egg proteins, soy proteins, lupine proteins, rice proteins, pea proteins and wheat proteins.
  • the disulfide cross-linked protein-based matrix in the present encapsulates can, for example, be formed by a process that involves the following steps: • providing an aqueous solution of a protein that is capable of forming disulfide cross-links;
  • the activation step in the aforementioned process is a special form of protein denaturation and is crucial for the formation of disulphide cross-links between activated protein aggregates during the drying step.
  • the activated protein aggregates are formed by irreversible denaturation of dissolved protein molecules, resulting in exposure of thiol groups that have the ability and accessibility to form disulfide bridges.
  • the reactive thiol groups of denatured protein molecules react together to form disulfide bridges.
  • aggregates comprising a multitude of cross-linked protein molecules are formed.
  • Activated protein aggregates can be prepared by various methods, such as heating, high pressure treatment etc.
  • the resulting protein reactivity is determined by the overall treatment conditions (shear, protein concentration, type of protein, protein composition, type and concentration of salts, pH, other ingredients such as sugars and polysaccharides, fats).
  • the activated aggregates used in the preparation of the present encapsulates exhibit a reactivity of at least 5.0 ⁇ mol thiol groups per gram of activated protein aggregates, as determined in the Ellman's assay (Ellman, G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 1959, 82, 70-77).
  • the protein-based probiotic encapsulates of the present invention can be produced through different manufacturing processes that all have in common that first a suspension is formed of activated protein aggregates. The suspension is then sprayed onto the probiotic component, thus forming a shell layer of protein around the probiotic.
  • the activated protein aggregates are cross-linked in such a way that the probiotics becomes trapped within the cross-linked protein-based matrix.
  • This cross-linking can be achieved by subjecting the suspension to a heat treatment or ultra high pressure. Alternatively, cross-linking may be brought about by contacting the activated aggregates in the interfacial layer with an oxidizing agent.
  • one aspect of the invention relates to an encapsulate comprising a protein-based encapsulation matrix that envelops one or more probiotic bacteria, preferably Gram-positive probiotic bacterial strains; said encapsulate having a mass weighted average diameter in the range of 0.5-5000 ⁇ m, wherein the protein-based encapsulation matrix contains at least 10 wt. % of a protein that has been cross-linked by means disulfide cross-links, said protein-based matrix further being characterized in that: i.
  • less than 75 wt.%, preferably less than 40 wt.% of the protein contained in the protein- based matrix can be dissolved when 75 mg of the encapsulate is dispersed in 50 ml distilled water having a temperature of 5 0 C at any pH within the range of 3.0-7.0; ii. the weight percentage of the protein that can be dissolved is at least a factor 1.3 higher when in the procedure under i) the distilled water is replaced by an aqueous solution of 2 wt.% dithiothreitol (DTT).
  • DTT dithiothreitol
  • solubility tests and the solubility tests described elsewhere in this document the pH of the distilled water or the DTT solution is adjusted with the help of HCl and solubility is measured 16 hours after the encapsulate was dispersed in the liquid. During this period the mixture is continuously gently stirred in order to prevent 'clumping' of the encapsulate particles.
  • solubility test i) and ii) pH is adjusted to achieve maximum protein solubility within the pH range of 3.0-7.0.
  • the poor solubility of the cross-linked protein-based matrix in distilled water is indicative for the high level of cross-linking of the present probiotic encapsulates.
  • the protein-based matrix of the present encapsulate would exhibit a much higher water solubility. This can be demonstrated by repeating the solubility test i) using an aqueous dithiothreitol (DTT) solution instead of distilled water. Since DTT reduces disulfide bonds and maintains the monothiols in a reduced state, the difference in solubility observed in the solubility tests with the DTT solution and distilled water is indicative of the level of disulfide cross-linking.
  • DTT dithiothreitol
  • encapsulate refers to a particulate material.
  • the individual particles within the encapsulate can consist of clearly identifiable discrete particles, but they can also consists, for instance, of a cluster of (micro-)particles, e.g. as a result of agglomeration.
  • protein refers to a polymer made of amino acids arranged in a chain and joined together by peptide bonds between the carboxyl and amino groups of adjacent amino acid residues. Typically, the protein contains at least 10 amino acid residues.
  • the protein employed in accordance with the present invention can be, for instance, an intact naturally occuring protein, a protein hydrolysate or a synthesised protein.
  • the invention pertains to encapsulated probiotic bacteria, and methods for obtaining such encapsulates.
  • the probiotic bacteria of the invention are preferably Gram-positive probiotic bacteria.
  • Gram positive probiotic encompasses any lactic acid bacteria (LAB).
  • lactic acid bacteria is used herein to refer to bacteria, which produce lactic acid as a product of fermentation, including e.g. bacteria of the genus Lactobacillus, Streptococcus, Lactococcus, Oenococcus, Leuconostoc, Pediococcus, Carnobacterium, Propionibacterium, Enterococcus and Bifidobacterium.
  • the lactic acid bacterial strains of the invention are "probiotics” or “probiotic strains”, which term herein refers to a strain of live bacteria, which have a beneficial effect on the host when ingested (e.g. enterally or by inhalation) by a subject.
  • a "subject” refers herein to a human or non- human animal, in particular a vertebrate.
  • the preferred LAB are Lactobacillus and Streptococcus, particularly Lactobacillus. Most preferred are Lacobacillus acidophilus, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus johnsonii, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus and Lactobacillus salivarius.
  • a suitable example of a Streptococcus strain is Streptococcus thermophilus.
  • Preferrred Bifidobacterium are Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium infantis and Bifidobacterium longum.
  • a suitable Enterococcus is Enterococcus faecium.
  • a preferred Lactococcus is Lactococcus lactis.
  • PCT/NL2007/050233 which was not published prior to the filing date of the present application, contains an example in which a probiotic powder in general is encapsulated by spray drying a pre-emulsion containing reactive whey protein aggregates onto extruded mixture of polymer and a probiotic powder. No specific probiotic strains are disclosed therein.
  • the present invention enables the preparation of encapsulates containing substantial levels of probiotics.
  • the probiotic materials in the encapsulate represent at least 1 wt.%, more preferably at least 5 wt.%, even more preferably at least 10 wt.% and most preferably at least 20 wt.% of the encapsulate.
  • the probiotic materials represent not more than 90 wt.%, preferably less than 70 wt% of the encapsulate.
  • the weight percentage of probiotic materials is calculated on the encapsulate exclusive any coating layers that may have been applied onto the (core) encapsulate.
  • the high payload of probiotic materials that can advantageously be achieved in the encapsulates of the present invention is reflected in a high probiotic to protein ratio.
  • the probiotics in the probiotic materials and the protein in the protein-based encapsulation matrix are contained in the encapsulate in a weight ratio probiotic : protein of 1:8 to 200:1, preferably in a weight ratio of 1:4 to 10:1.
  • the protein-based encapsulation matrix, besides cross-linked protein may suitably contain other matrix components, such as carbohydrates (e.g. fibers, inulin, maltodextrin, lactose, sucrose, glucose, galactose), hydrocolloids (e.g.
  • the protein-based encapsulation matrix contains at least 20 wt.%, even more preferably at least 40 wt.% and most preferably at least 60 wt.% of a protein that has been cross-linked by means disulfide cross-links.
  • the protein that has been cross- linked by disulfide cross-links in its native form comprises at least three cystein residues per molecule, even more preferably at least 4 and most preferably at least 5 cystein residues per molecule.
  • the whey proteins ⁇ -lactoglobulin and ⁇ -lactoglobulin contain 5 and 8 cystein residues per molecule, respectively.
  • cystein residues that are bound to other cystein residues by means of a disulfide bond.
  • the protein that has been cross-linked by disulfide cross-links in native form preferably comprises at least about 1 or even 2 cystein residues per 500, especially per 400 amino acids, more preferably at least 1 or even 2 cystein residues per 300 or 200 amino acids, even more preferably per 100, 30 or 20 amino acids.
  • the average molecular weight of the protein is preferably at least 5, 10, 15, 20, 50, 100, 200, 250 or more kDa as determined by SDS-PAGE analysis.
  • the protein that has been cross-linked by disulfide cross-links advantageously contains at least 30 amino acid residues, more preferably at least 50 amino acid residues and most preferably at least 60 amino acid residues.
  • proteins that are capable of forming disulfide cross-links and that can suitably be employed in the protein based matrix include whey proteins and plant proteins, such as wheat proteins, soybean proteins, pea proteins, lupine proteins, canola or oilseeds rape proteins, maize proteins, rice proteins, and many others.
  • animal proteins such as bovine serum albumin, one or more blood proteins, one or more egg proteins may be used.
  • certain microbial proteins such as one or more bacterial proteins and/or fungal proteins (including yeast proteins) can be used.
  • the protein in the protein-based matrix that has been cross-linked by disulfide cross- links is preferably selected from one or more of the group consisting of whey proteins, egg proteins, soy proteins, lupine proteins, rice proteins, pea proteins, wheat proteins and combinations thereof. Even more preferably, said cross-linked protein is selected from the group consisting of whey proteins, egg proteins, soy proteins and combinations thereof. Most preferably, the protein is a whey protein or a combination of whey proteins.
  • the encapsulates of the present invention contain a protein-based matrix that is made up of macromolecules consisting of a hundreds or thousands of protein molecules that have been cross-linked by disulfide bonds.
  • the protein that has been cross-linked by disulfide cross-links exhibits a number weighted average degree of polymerisation of at least 500 more preferably of at least and most preferably of at least 1000.
  • the degree of polymerisation equals the total number of protein molecules that are linked together in a single cross-linked macromolecule.
  • the encapsulates of the present invention typically have a mass weighted average diameter in the range of 1-2000 ⁇ m. Even more preferably the mass weighted average diameter of the present encapsulates is in the range of 5-1000 ⁇ m, most preferably in the range of 5-500 ⁇ m.
  • the present encapsulate can be prepared in the form of a granulate with a relatively large diameter by e.g. extrusion or alternatively by agglomerating an encapsulate with a smaller particle distribution. Encapsulates with a relatively small particle size can be obtained by means of e.g. spray drying.
  • the particle size distribution of the encapsulate can suitably be determined in a manner well known to a skilled person using a set of sieves with different well-defined mesh sizes.
  • the present invention also encompasses encapsulates in which protein in the protein- based matrix has not only been cross-linked by disulfide bonds, but in which additional cross- linking mechanisms have been used to cross-link the protein molecules.
  • additional cross-linking mechanisms include the use of gluteraldehyde as cross-linking agent and the use of transglutaminase.
  • the protein in the present encapsulate has not been cross-linked in any other way than by disulfide cross-links.
  • the poor water solubility of the protein-based matrix of the present encapsulate is associated with the high level of disulfide cross-linking within said matrix. Without these cross-links the protein-based matrix normally has a much higher water solubility.
  • the protein-based matrix is characterized in that more than 60 wt.%, more preferably more than 80 wt.% and most preferably at least 90 wt.% of the protein contained in the protein-based matrix dissolves in an aqueous solution of 2 wt.% DTT having a temperature of 25 0 C and a pH in the range of 3.0-7.0.
  • the protein-based probiotic encapsulates according to the present invention exhibit the special property that the protein contained in the protein-based matrix exhibits very poor water solubility as a result of the disulfide cross-linking. This poor water solubility is also apparent within a broad pH range at near ambient conditions. Consequently, in a preferred embodiment, the protein-based matrix is characterized in that less than 70 wt.%, more preferably less than 40 wt.% and most preferably less than 25 wt.% of the protein contained in the protein-based matrix can be dissolved when 75 mg of the encapsulate is dispersed in 50 ml distilled water having a temperature of 25 0 C at any pH within the range of 3.0-7.0.
  • the weight percentage of the protein that can be dissolved is at least a factor 1.3 higher when in the aforementioned procedure the distilled water is replaced by an aqueous solution of 2 wt.% DTT.
  • the protein-based matrix is characterised in that: i. less than 40 wt.%, more preferably less than 25 wt.% of the protein contained in the protein-based matrix can be dissolved when 75 mg of the encapsulate is dispersed in 50 ml distilled water having a temperature of 25 0 C at any pH within the range of 3.0-7.0; ii.
  • the weight percentage of the protein that can be dissolved is at least a factor 2 higher when in the aforementioned procedure the distilled water is replaced by an aqueous solution of 2 wt.% DTT.
  • the protein-based matrix is characterized in that less than 40 wt.%, more preferably less than 25 wt.% of the protein- based matrix can be dissolved when 75 mg of the encapsulate is dispersed in 50 ml distilled water having a temperature of 25 0 C at any pH within the range of 1.0-8.0.
  • the protein-based matrix is characterised in that: i.
  • less than 40 wt.%, more preferably less than 25 wt.% of the protein contained in the protein-based matrix can be dissolved when 75 mg of the encapsulate is dispersed in 50 ml distilled water having a temperature of 25 0 C at any pH within the range of 1.0-8.0; ii. the weight percentage of the protein that can be dissolved is at least a factor 2 higher when in the aforementioned procedure the distilled water is replaced by an aqueous solution of 2 wt.% DTT.
  • the number of probiotic celss per gram of encapsulate can vary widely, e.g. in the range from 10 6 - 10 12 cfu/g (colony forming units per gram encapsulate), preferably in the range from 10 7 - 10 11 cfu/g, more preferably in the range of 10 8 - 10 10 cfu/g.
  • the encapsulate of the present invention advantageously is substantially water-free. Typically, the encapsulate contains less than 20 wt.% of water. Even more preferably the water content does not exceed 10 wt.%.
  • the present invention also encompasses an embodiment in which the encapsulate comprising the probiotic materials and the protein-based matrix is coated with one or more protective layers. The use of such coating layers may even further improve the survival rate of the probiotics-containing encapsulate. Such coatings may also be applied in order to make the encapsulate less sensitive to conditions of shear.
  • the present encapsulate contains at least on coating layer that contains at least 60 wt.% of one or more components selected from the group consisting of lipids (including waxes and low PUFA fats), polyols (such as: glycerol, xylitol), menthol, glyceryl triacetate, di-(2-ethylhexyl) adipate, plasticizers (such as glycerol, glyceryl triacetate and/or di-(2- ethylhexyl) adipate, or others), or mixtures of two or more plasticizers; sugars (such as for example: lactose, sucrose, glucose, galactose), hydrocolloids (such as for example: gum Arabic, alginate, pectin, starch, xanthan gum, carrageenan, guar gum, locust bean gum, tara gum, gellan gum), salts (such as for example: sodium salts,
  • the present invention also provides a method of producing an encapsulate as defined herein before, said method comprising:
  • aqueous solution of protein that is capable of forming disulfide cross-links can also contain non-dissolved protein and other non-dissolved components.
  • the aqueous protein solution (which optionally further comprises additives) is submitted to a protein activation treatment.
  • the nature of this treatment is not essential, as long as the protein becomes sufficiently activated for further use.
  • the activation treatment is preferably a heat treatment
  • other methods may also be suitable for achieving the same degree of protein activation, such as application of high pressure, shear forces, etc.
  • suitable methods for achieving adequate protein reactivity are heat treatment, microwave treatment, high pressure, shear, unfolding with urea, and combinations thereof. The skilled person can easily determine whether the treatment results in sufficiently activated (reactive) protein aggregates.
  • the temperature and time required for obtaining the minimum reactivity depends on the types of protein used and other conditions, such as applied shear, pH of the solution, salts, etc.
  • heat treatment of a solution of 9%wt. whey proteins (BiPROTM; Davisco, USA) in demineralized water for 30 minutes holding time at 90 0 C in a water bath without stirring resulted in a reactivity of more than 15 ⁇ mol per gram of protein.
  • the treatment should be sufficient to result in protein aggregates having a reactivity of at least 5.0 ⁇ mol thiol groups per gram of protein.
  • the reactivity achieved is at least 10 ⁇ mol/g, more preferably at least 15 ⁇ mol/g, even more preferably at least 20 ⁇ mol/g and most preferably at least 25 ⁇ mol/g.
  • Reactivity is required to enable covalent cross-linking of the protein aggregates.
  • the reactivity is defined as the number of reactive thiol groups per gram of protein. Exposure of reactive thiol groups, which leads to their reactivity, can be achieved by e.g. heat-treatment.
  • the aforementioned reactivity can suitably be determined at pH 7 according to the Ellman's assay (Ellman, 1959 vide supra).
  • the absorbance is measured at 20-25 0 C.
  • the value after 30 minutes of incubation with DTNB is taken to calculate the reactivity.
  • the reactivity is measured by determining the concentration of thiol groups (in mM) in a 2 wt.% protein solution.
  • the aqueous suspension containing the activated protein aggregates typically contains from 0.1-25 wt.% of the protein capable of forming disulfide links. More preferably, said suspension contains from 0.5-15 wt.% of the protein capable of forming disulfide links.
  • the activated protein aggregates in the suspension preferably have a volume weighted average diameter in the range of 1-1000 nanometers, more preferably in the range of 2-250 nanometers, even more preferably in the range of 2-100 nanometers.
  • the aqueous suspension comprising the reactive protein aggregates (and optionally other additives) is advantageously sprayed onto a core material to form protein- coated core particles, preferably having a volume weighted average diameter in the range of 0.5-5000 ⁇ m, more preferably in the range of 1-2000 ⁇ m, most preferably 5 - 1000 ⁇ m, particularly 5-500 ⁇ m.
  • the spraying may be performed in air or in a gas.
  • the gas has low or zero reactivity towards the thiol groups contained in the activated protein aggregates.
  • gases that may be used in accordance with the invention include nitrogen, carbon dioxide, air, argon, helium and combinations thereof.
  • the suspension of activated protein aggregates is typically sprayed in air or gas by means of a nozzle.
  • spraying of the activated protein aggregate suspension onto the core particles and subsequent drying may be performed using e.g. fluidized bed or spouted bed equipment.
  • fluidized bed or spouted bed equipment Such equipment is available in the art, see e.g. Fluid bed coater GPCG 1.1 with Wurster insert (Glatt GmbH).
  • Spraying advantageously involves a temperature in excess of 30 0 C, even more preferably in excess of 40 0 C.
  • initial cross-linking of the protein aggregates can be instigated.
  • partially cross- linking the protein aggregates in the suspension droplets the stability of these droplets is enhanced, which makes it easier to oxidatively cross-link the protein aggregates in a next step.
  • the aqueous suspension is dispensed into a hot gas to remove water and to convert the droplets into partially cross-linked protein-based particles which are subsequently contacted with the oxidizing agent. Particularly good results are obtained if the dispensed suspension is contacted with the hot gas in countercurrent fashion.
  • the present method preferably comprises spraying the suspension of protein aggregates onto core particles, e.g. in a fluidized bed, said core particles containing the probiotic to be encapsulated.
  • the suspension droplets are deposited on the surfaces of the core particles.
  • the core particles containing said one or more probiotics comprise at least 5 wt.%, more preferably 5-98 wt%, most preferably 10-50 wt% of a bulk ingredient.
  • a bulk ingredient may comprise or consist of hydrocolloids (e.g. carboxymethylcellulose, starch, maltodextrin) and/or fats and/or waxes and/or carbohydrates (e.g. sugars) and/or proteins.
  • said core particles further comprise one or more of the components selected from the group consisting of fibres, vitamins, minerals, peptides, polyphenols, fatty acids, oils, drugs, bioactive components, flavours, colourants, gas and combinations thereof.
  • the probiotic can be entrapped within the core particle made by e.g. extrusion or other technique, such as spheronization.
  • the particles referred to in the above method are particles containing one ore more probiotics.
  • the core material may contain one or more additional (sensitive) additives, such as an enzyme , a prebiotic, a vitamin, a polyunsaturated fatty acid (PUFA), a flavour (e.g. a bitter component, a salty component, an acid components, etc.).
  • additional (sensitive) additives such as an enzyme , a prebiotic, a vitamin, a polyunsaturated fatty acid (PUFA), a flavour (e.g. a bitter component, a salty component, an acid components, etc.
  • PUFA polyunsaturated fatty acid
  • flavour e.g. a bitter component, a salty component, an acid components, etc.
  • any component preferably food-grade, which benefits from protection against the environment, such as oxygen, moisture, acid conditions, interaction with food matrix, temperature, any part of the intestinal tract environment (e.g. mouth / saliva, stomach acids, intestine, etc.) etc. may be used.
  • the core particles are preferably spherical. Suitable core particles include particles of at least 50 ⁇ m. Preferably the core particles have a diameter of at least 100 ⁇ m even more preferably of at least 200 ⁇ m and most preferably of at least 300 ⁇ m. Typically, the diameter of the core particles does not exceed 5000 ⁇ m.
  • probiotics are provided as a concentrated suspension of cells to the aqueous suspension of activated protein aggregates.
  • the invention also pertains to a method of producing a probiotic encapsulate, said method comprising the aforementioned steps a) and b),and further comprising a step c) of providing a concentrated suspension of probiotic cells, preferably containing at least 10 8 cfu/g of one or more probiotics, to said suspension of protein aggregate, and spraying said suspension; and d) forming disulfide cross-links between the activated protein aggregates.
  • the aforementioned spraying conditions may also be applied in the present case.
  • one or more (food-grade) additives may be added to the protein aggregates, either before the activation treatment and/or after the activation treatment, but prior to the cross-linking treatment.
  • the additives are not reactive towards the activated protein aggregates, e.g. the additives do not react with free thiol groups as this would interfere with the cross-linking of the protein.
  • the exception to this concerns cross- linkers which will assist in cross-linking the activated protein aggregates.
  • the protein aggregates deposited on the surface of the core particles may get further cross-linked as soon as they have been deposited onto the core particles, e.g. by applying heat treatment or by applying core particles that contain a suitable oxidizing agent.
  • the formation of the disulfide cross-links is brought about by subjecting the dispensed droplets to heat.
  • a convenient way of subjecting the dispensed droplets to a heat treatment is to dispense the aqueous suspension into a hot gas and/or by spraying the aqueous suspension onto hot core particles.
  • cross-linking may be established by pressurization to a pressure in excess of 50 MPa, more preferably at least 100 MPa.
  • Yet another method of establishing further cross-linking of the activated protein aggregates is by oxidizing, using an oxidizing agent.
  • the oxidizing agent according to the invention has the ability to oxidize the free thiol groups in the protein aggregates to form disulfide cross-links. Any oxidizing agent having this ability may be used in accordance with the invention.
  • the oxidizing agent is selected from the group consisting of salts, oxides or ligands of transition metals, reactive oxygen compounds (e.g. hydrogen peroxide) and oxidizing enzymes (oxidoreductases) and combinations thereof.
  • transition metals that can be used in the form of salts or ligands in the present method are selected from the group consisting of copper, iron, manganese, zinc, ruthenium, cobalt and combinations thereof. Most preferably, the transition metal is selected from the group consisting of copper (Cu(II)), iron (Fe(III)), manganese, nickel, zinc and combinations thereof. According to another preferred embodiment, the present method employs a salt of a transition metal, e.g. a transition metal oxide or a transition metal halide. The term "salt" as used herein also encompasses the use of dissociated salts.
  • the protein aggregates are contacted with the one or more transition metals in an aqueous medium containing at least 0.001 mM of the said transition metals, more preferably 0.001-500 mM, most preferably 0.01-100 mM.
  • said transition metals are contained in the aqueous medium in the form of cations having a valency of at least 2. Oxidoreductases (i.e. enzymes classified under the Enzyme Classification number E.C. 1
  • Oxidoreductases in accordance with the Recommendations (1992) of the International Union of Biochemistry and Molecular Biology (IUBMB)) are enzymes catalyzing redox reaction. Suitable examples include laccases or related enzymes which act on molecular oxygen and yield water; oxidases, which act on molecular oxygen and yield peroxide; and peroxidases which act on peroxide and yield water.
  • the oxidizing agent is an enzyme selected from the group consisting of oxidases, peroxidases, laccases and combinations thereof.
  • the oxidizing enzyme is selected from the group consisting of glutathione peroxidase, horseradish peroxidase, microperoxidase, coprinus cinereus oxidase, chloroperoxidase, lactoperoxidase, manganese peroxidase and combinations thereof. Most preferably, the oxidizing enzyme is selected from the group consisting of glutathione peroxidase, horseradish peroxidase, coprinus cinereus oxidase, manganese peroxidase and combinations.
  • the present invention also encompasses the formation of encapsulates in which protein in the protein-based matrix has not only been cross-linked by disulfide bonds, but in which additional cross-linking mechanisms have been used to crosslink the protein molecules.
  • additional cross-linking mechanisms include the aforementioned use of gluteraldehyde and/or transglutaminase as cross-linking agents.
  • the method of the only involves disulfide cross-linking.
  • the aforementioned characteristics of the protein layer thickness and the volume- weighted average diameter are not expected to change significantly during cross-linking.
  • Another aspect of the present invention relates to a foodstuff, a beverage, a nutritional supplement or animal feed containing from 0.05-60 wt.% of an encapsulate as defined herein.
  • Yet another aspect of the invention relates to a method of preparing a foodstuff, a beverage, a nutritional supplement or animal feed, said method comprising incorporating from 0.05-60 wt.% of an encapsulate according to the present invention.
  • Example 1 Preparation of encapsulated probiotics
  • Protein solutions were prepared by mixing 70 g of whey protein isolate (BiPROTM; Davisco, USA) in 700 g of demineralized water at room temperature (stirred for 2 h).
  • Reactive protein aggregates were prepared by heating the whey protein isolate solution at 90°C during 30 min in a water bath. The solution was further cooled down in ice and then brought to room temperature.
  • the reactivity of the particles was determined using the DTNB -method as described before. The reactivity was about 20 ⁇ mol thiol groups per gram of protein.
  • probiotic powder was containing a lactic acid bacteria
  • spouted bed Procell technology
  • Particles were made spherical by agglomeration/erosion in the spouted bed with an aqueous solution containing 1 wt.% methylcellulose and 5 wt.% trehalose as binder.
  • the material thus obtained is called core material.
  • the activated protein mixture prepared as described above is then sprayed using a fluidized bed coater (Glatt, Germany) onto 281 g spherical core material comprising the lactic acid bacteria.
  • the encapsulates were then tested under stomach conditions and the survival of the pribiotic cells in the encapsulates was higher than that of the non encapsulated probiotic cells.
  • Example 2 Solubility assay of the encapsulates containing the lactic acid bacteria
  • the solubility of the encapsulation matrix of the probiotica-containing encapsulates of example 1 was tested at pH 7 at 20 0 C in distilled water and in an aqueous solution of 2 wt.% dithiothreitol (DTT). To this end, 75 mg of the encapsulate was dispersed in 50 ml distilled water and 75 mg of the encapsulate was dispersed in 50 ml of an aqueous solution of 2 wt.% dithiothreitol (DTT). The capsules were gently stirred overnight. The supernatant was filtered and the soluble proteins were quantified by spectrophotometer reading at 280 nm.
  • DTT dithiothreitol
  • the encapsulate prepared with reactive protein aggregates (Example 1) were almost insoluble in water at pH 7, whereas they were soluble in the aqueous solution of 2 wt.% dithiothreitol (DTT).
  • DTT dithiothreitol
  • Example 3 Activity assay of the encapsulates containing the lactic acid bacteria The activity of the lactic acid bacteria encapsulated in the core material and the probiotica- containing encapsulates of example 1 was tested in a MRS agar (Merck) medium after incubation for 3 days at 37°C.
  • Table 2 showed that the probiotica-containing encapsulates of Examples 1 had an activity of 1.20 10 10 cfu/g (colony forming units per gram material). This showed that the probiotica-containing encapsulates had a sufficient high activity to be applied in food applications.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne une capsule qui comprend une matrice d'encapsulation à base de protéines qui enveloppe une ou plusieurs bactéries probiotiques, de préférence des bactéries probiotiques Gram-positives ; ladite capsule ayant un diamètre moyen pondéré en masse dans la plage de 1 à 5000 µm, la matrice d'encapsulation à base de protéines contenant au moins 10 % en poids d'une protéine qui a été réticulée au moyen de liaisons réticulaires de disulfure, ladite matrice à base de protéines étant en outre caractérisée en ce que : (i) moins de 75 % en poids, de préférence moins de 40 % en poids de la protéine contenue dans la matrice à base de protéines, peuvent être dissous lorsque 75 mg de la capsule sont dispersés dans 50 ml d'eau distillée dont la température est de 5 °C à tout pH dans la plage de 3,0 à 7,0 ; et (ii) le pourcentage en poids de la protéine qui peut être dissous est d'au moins un facteur 1,3 fois supérieur lorsque, dans la procédure en i), l'eau distillée est remplacée par une solution aqueuse de 2 % en poids de dithiothréitol (DTT). La capsule selon la présente invention présente un taux de survie élevé lorsque digérée et peut être produite par un procédé de fabrication robuste et relativement simple. L'invention concerne également un procédé de fabrication de la capsule ci-dessus mentionnée.
PCT/NL2008/000266 2007-11-29 2008-12-01 Capsules de probiotiques à base de protéines Ceased WO2009070012A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07121921 2007-11-29
EP07121921.6 2007-11-29

Publications (1)

Publication Number Publication Date
WO2009070012A1 true WO2009070012A1 (fr) 2009-06-04

Family

ID=40457022

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2008/000266 Ceased WO2009070012A1 (fr) 2007-11-29 2008-12-01 Capsules de probiotiques à base de protéines

Country Status (1)

Country Link
WO (1) WO2009070012A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012142153A1 (fr) * 2011-04-15 2012-10-18 Pepsico, Inc Système d'encapsulation pour la protection de probiotiques pendant un traitement
EP2925300A4 (fr) * 2012-11-29 2016-08-03 Progel Pty Ltd Microparticules comprenant un probiotique, un réactif de réticulation, une protéine dénaturée, un agent ramollissant à base de polyol et du tréhalose
WO2017105990A1 (fr) 2015-12-14 2017-06-22 Massachusetts Institute Of Technology Microorganismes à encapsulation en polymères mucoadhésifs sensibles au ph
CN110628684A (zh) * 2019-10-25 2019-12-31 华中农业大学 一种乳酸菌增菌剂及在乳酸菌高密度发酵中的应用
WO2020229670A1 (fr) * 2019-05-16 2020-11-19 Chr. Hansen A/S Procédés d'encapsulation
WO2021185386A1 (fr) 2020-05-21 2021-09-23 Bialtec S.A.S. Formulations d'additifs fonctionnels et leur procédé d'encapsulation avec une matrice hydrophobe
WO2022040129A1 (fr) * 2020-08-18 2022-02-24 Foodscience Corporation Composé antioxydant encapsulé dans une protéine de lactosérum polymérisée et son procédé de préparation
CN115399461A (zh) * 2022-08-30 2022-11-29 常熟理工学院 一种益生菌缓释果冻及其制备方法和应用
DE102021117120A1 (de) 2021-07-02 2023-01-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein Mikroverkapselung von Ammoniumphosphat-bildenden Bakterien und deren Verwendung

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037683A2 (fr) * 1999-11-24 2001-05-31 Mateescu, M-Alexandru Films biologiques a base de proteines et de polysaccharides
US20040013732A1 (en) * 2001-09-25 2004-01-22 Michael Farber Starch-based delivery system for creatine
WO2004012520A2 (fr) * 2002-08-01 2004-02-12 The Regents Of The University Of California Procede et compositions destines a preparer et a delivrer des lipides soustraits a la degradation ruminale, autres nutrients et medicaments
US20040223956A1 (en) * 2000-12-18 2004-11-11 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
WO2007136263A1 (fr) * 2006-05-22 2007-11-29 Nizo Food Research B.V. Particules encapsulées par une protéine
WO2007150047A1 (fr) * 2006-06-22 2007-12-27 Martek Biosciences Corporation Compositions de composé labile encapsulées et leurs procédés de fabrication
WO2008113663A1 (fr) * 2007-03-20 2008-09-25 Unilever N.V. Procédé de fabrication d'un produit comestible composé de fruits et d'acides gras polyinsaturés sous forme d'omega-3 et de fer
WO2008120975A1 (fr) * 2007-03-30 2008-10-09 Friesland Brands B.V. Encapsulation à l'aide d'une suspension double
WO2008143507A2 (fr) * 2007-05-21 2008-11-27 Nizo Food Research B.V. Produits d'encapsulation à base de protéine réticulée par oxydation

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037683A2 (fr) * 1999-11-24 2001-05-31 Mateescu, M-Alexandru Films biologiques a base de proteines et de polysaccharides
US20040223956A1 (en) * 2000-12-18 2004-11-11 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
US20040013732A1 (en) * 2001-09-25 2004-01-22 Michael Farber Starch-based delivery system for creatine
WO2004012520A2 (fr) * 2002-08-01 2004-02-12 The Regents Of The University Of California Procede et compositions destines a preparer et a delivrer des lipides soustraits a la degradation ruminale, autres nutrients et medicaments
WO2007136263A1 (fr) * 2006-05-22 2007-11-29 Nizo Food Research B.V. Particules encapsulées par une protéine
WO2007150047A1 (fr) * 2006-06-22 2007-12-27 Martek Biosciences Corporation Compositions de composé labile encapsulées et leurs procédés de fabrication
WO2008113663A1 (fr) * 2007-03-20 2008-09-25 Unilever N.V. Procédé de fabrication d'un produit comestible composé de fruits et d'acides gras polyinsaturés sous forme d'omega-3 et de fer
WO2008120975A1 (fr) * 2007-03-30 2008-10-09 Friesland Brands B.V. Encapsulation à l'aide d'une suspension double
WO2008143507A2 (fr) * 2007-05-21 2008-11-27 Nizo Food Research B.V. Produits d'encapsulation à base de protéine réticulée par oxydation

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012142153A1 (fr) * 2011-04-15 2012-10-18 Pepsico, Inc Système d'encapsulation pour la protection de probiotiques pendant un traitement
US9788563B2 (en) 2011-04-15 2017-10-17 Pepsico, Inc. Encapsulation system for protection of probiotics during processing
EP2925300A4 (fr) * 2012-11-29 2016-08-03 Progel Pty Ltd Microparticules comprenant un probiotique, un réactif de réticulation, une protéine dénaturée, un agent ramollissant à base de polyol et du tréhalose
US10188609B2 (en) 2012-11-29 2019-01-29 Progel Pty Ltd Microparticles comprising a probiotic, cross-linkable reagent, a denatured protein, polyol plasticiser and trehalose
WO2017105990A1 (fr) 2015-12-14 2017-06-22 Massachusetts Institute Of Technology Microorganismes à encapsulation en polymères mucoadhésifs sensibles au ph
US10548844B2 (en) 2015-12-14 2020-02-04 Massachusetts Institute Of Technology pH-responsive mucoadhesive polymeric encapsulated microorganisms
WO2020229670A1 (fr) * 2019-05-16 2020-11-19 Chr. Hansen A/S Procédés d'encapsulation
CN110628684A (zh) * 2019-10-25 2019-12-31 华中农业大学 一种乳酸菌增菌剂及在乳酸菌高密度发酵中的应用
WO2021185386A1 (fr) 2020-05-21 2021-09-23 Bialtec S.A.S. Formulations d'additifs fonctionnels et leur procédé d'encapsulation avec une matrice hydrophobe
WO2022040129A1 (fr) * 2020-08-18 2022-02-24 Foodscience Corporation Composé antioxydant encapsulé dans une protéine de lactosérum polymérisée et son procédé de préparation
CN116209450A (zh) * 2020-08-18 2023-06-02 食品科学有限责任企业 聚合乳清蛋白包封的抗氧化化合物及其制备方法
US11766407B2 (en) 2020-08-18 2023-09-26 Foodscience Corporation Polymerized whey protein encapsulated antioxidant compound and a process for preparation of same
US12194155B2 (en) 2020-08-18 2025-01-14 Foodscience Llc Polymerized whey protein encapsulated antioxidant compound and a process for preparation of same
DE102021117120A1 (de) 2021-07-02 2023-01-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein Mikroverkapselung von Ammoniumphosphat-bildenden Bakterien und deren Verwendung
DE102021117120B4 (de) 2021-07-02 2023-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein Verfahren zur Herstellung eines phosphorhaltigen Düngemittels unter Verwendung von Mikrokapseln umfassend Ammoniummagnesiumphosphat-bildende Bakterien und eine Magnesiumquelle
CN115399461A (zh) * 2022-08-30 2022-11-29 常熟理工学院 一种益生菌缓释果冻及其制备方法和应用

Similar Documents

Publication Publication Date Title
WO2009070012A1 (fr) Capsules de probiotiques à base de protéines
Solanki et al. Development of microencapsulation delivery system for long‐term preservation of probiotics as biotherapeutics agent
JP6240386B2 (ja) プロバイオティクスの安定化
Mao et al. Development of soy protein isolate-carrageenan conjugates through Maillard reaction for the microencapsulation of Bifidobacterium longum
US20090238885A1 (en) Protein encapsulated particles
Kent et al. Probiotic bacteria in infant formula and follow-up formula: Microencapsulation using milk and pea proteins to improve microbiological quality
Shori Microencapsulation improved probiotics survival during gastric transit
Martín et al. Microencapsulation of bacteria: A review of different technologies and their impact on the probiotic effects
Nag et al. Microencapsulation of probiotic bacteria using pH-induced gelation of sodium caseinate and gellan gum
Shi et al. Encapsulation of Lactobacillus bulgaricus in carrageenan-locust bean gum coated milk microspheres with double layer structure
Manojlović et al. Encapsulation of probiotics for use in food products
Augustin et al. Encapsulation of bioactives
US9480276B2 (en) Dry food product containing live probiotic
US20110045147A1 (en) Protein-based oil encapsulates
WO2009070011A1 (fr) Procédé de fabrication de capsules à base de protéine
CN102170791B (zh) 包含益生菌复合物的珠粒的制备
Nawong et al. Entrapment in food-grade transglutaminase cross-linked gelatin–maltodextrin microspheres protects Lactobacillus spp. during exposure to simulated gastro-intestinal juices
Augustin et al. Use of milk proteins for encapsulation of food ingredients
Das et al. Microencapsulation of probiotic bacteria and its potential application in food technology
WO2008143507A2 (fr) Produits d'encapsulation à base de protéine réticulée par oxydation
SG188301A1 (en) Process of producing shelf stable probiotic food
CN106387967A (zh) 一种含有益生菌和不饱和脂肪酸组合物的制备方法及该组合物的应用
Yin et al. Construction of double network gel for co-encapsulation of probiotics and capsaicin: Enhanced the physicochemical stability and controlled release
Li Development of microencapsulation-based technologies for micronutrient fortification in staple foods for developing countries
Nag Development of a microencapsulation technique for probiotic bacteria Lactobacillus casei 431 using a protein-polysaccharide complex: a thesis presented in partial fulfillment of the requirements of the degree of Masters of Technology in Food Technology at Massey University, Palmerston North, New Zealand

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08853638

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08853638

Country of ref document: EP

Kind code of ref document: A1